A Phase 2 Study of TRC105 (Anti-endoglin Antibody) With Abiraterone and With Enzalutamide in Metastatic, Castration Resistant Prostate Cancer Patients Progressing on Therapy
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Carotuximab (Primary) ; Abiraterone; Enzalutamide
- Indications Prostate cancer
- Focus Therapeutic Use
- 09 Nov 2019 Status changed from active, no longer recruiting to completed.
- 13 May 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated